PDF herunterladen
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2017; 77(12): 1291-1298
DOI: 10.1055/s-0043-122884
GebFra Science
Review/Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Zirkulierende Tumorzellen, zirkulierende Tumor-DNA und zirkulierende microRNA beim metastasierten Mammakarzinom – oder: Welche Rolle spielt die Liquid Biopsy beim Brustkrebs?

Artikel in mehreren Sprachen: English | deutsch
Arkadius Polasik
1   Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany
,
Marie Tzschaschel
1   Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany
,
Fabienne Schochter
1   Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany
,
Amelie de Gregorio
1   Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany
,
Thomas W. P. Friedl
1   Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany
,
Brigitte Rack
1   Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany
,
Andreas Hartkopf
2   Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Tübingen, Tübingen, Germany
,
Peter A. Fasching
3   Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Erlangen, Erlangen, Germany
,
Andreas Schneeweiss
4   Nationales Centrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Heidelberg, Germany
,
Volkmar Müller
5   Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
,
Jens Huober
1   Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany
,
Wolfgang Janni
1   Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany
,
Tanja Fehm
6   Klinik für Gynäkologie und Geburtshilfe, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 16. Juli 2017
revised 09. November 2017

accepted 12. November 2017

Publikationsdatum:
18. Dezember 2017 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Die Streuung von Tumorzellen und Entstehung solider Metastasen findet sowohl über das Lymph- als auch das Blutsystem statt. Der Nachweis zirkulierender Tumorzellen (CTCs) und der zirkulierenden Tumor-DNA (ctDNA) im venösen Blut ist sowohl beim frühen als auch beim metastasierten Mammakarzinom möglich. Ihre prognostische Relevanz wurde bereits mehrfach bewiesen. Dabei ist die repetitive Untersuchung der CTCs bzw. ctDNA im Sinne einer regelmäßigen „liquid biopsy“ jederzeit und problemlos möglich. Durch die zusätzlichen molekularen Analysen ist es möglich, Tumorcharakteristika und ihre Heterogenität, die mit möglichen Resistenzen einhergehen, zu definieren. Dies ermöglicht den Einsatz einer personalisierten und zielgerichteten Therapie, um neben einem verlängerten Gesamtüberleben auch die Verbesserung der Lebensqualität zu erreichen.

Schlüsselwörter

Brust - Her-2/neu (humaner epidermaler Wachstumsfaktor-Rezeptor) - Hormonrezeptor - Tumor der Brustdrüse - Metastase
 

  • References/Literatur

  • 1 Aktuelle Empfehlungen zur Diagnostik und Therapie primärer und metastasierter Mammakarzinome der Kommission MAMMA in der AGO e.V.. 2017 Online: http://www.ago-online.de last access: 09/2017
    PubMedSuche in Google Scholar
  • 2 Gerlinger M, Rowan AJ, Horswell S. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892
    CrossrefPubMedSuche in Google Scholar
  • 3 Paget S. The distribution of secondary growth in cancer of the breast. Lancet 1889; 133: 571-573
    CrossrefPubMedSuche in Google Scholar
  • 4 Braun S, Vogl FD, Naume B. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802
    CrossrefPubMedSuche in Google Scholar
  • 5 Janni W, Vogl FD, Wiedswang G. et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse – a European pooled analysis. Clin Cancer Res 2011; 17: 2967-2976
    CrossrefPubMedSuche in Google Scholar
  • 6 Fehm T, Muller V, Aktas B. et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 2010; 124: 403-412
    CrossrefPubMedSuche in Google Scholar
  • 7 Bidard F-C, Peeters DJ, Fehm T. et al. Clinical validity of circulating tumor cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2015; 15: 406-415
    PubMedSuche in Google Scholar
  • 8 Müller V, Riethdorf S, Rack B. et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 2012; 14: R118
    CrossrefPubMedSuche in Google Scholar
  • 9 Bidard FC, Peeters DJ, Fehm T. et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014; 15: 406-414
    CrossrefPubMedSuche in Google Scholar
  • 10 Rack B, Schindlbeck C, Jückstock J. et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 2014; 106: pii:dju066 doi:10.1093/jnci/dju066
    PubMedSuche in Google Scholar
  • 11 Janni W, Rack B, Terstappen LW. et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res 2016; 22: 2583-2593
    CrossrefPubMedSuche in Google Scholar
  • 12 Yang YF, Liao YY, Yang M. et al. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast. Med Oncol 2014; 31: 214
    CrossrefPubMedSuche in Google Scholar
  • 13 Heitz F, Barinoff J, du Bois O. et al. Differences in the receptor status between primary and recurrent breast cancer – the frequency of and the reasons for discordance. Oncology 2013; 84: 319-325
    CrossrefPubMedSuche in Google Scholar
  • 14 Somlo G, Lau SK, Frankel P. et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat 2011; 128: 155-163
    CrossrefPubMedSuche in Google Scholar
  • 15 Munzone E, Nolé F, Goldhirsch A. et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer 2010; 10: 392-397
    CrossrefPubMedSuche in Google Scholar
  • 16 Jäger BA, Finkenzeller C, Bock C. et al. Estrogen receptor and HER2 status on disseminated tumor cells and primary tumor in patients with early breast cancer. Transl Oncol 2015; 8: 509-516
    CrossrefPubMedSuche in Google Scholar
  • 17 Santinelli A, Pisa E, Stramazzotti D. et al. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008; 122: 999-1004
    PubMedSuche in Google Scholar
  • 18 Schramm A, Friedl TWP, Schochter F. et al. Association between HER2-phenotype on circulation tumor cells and primary tumor characteristics in women with metastatic breast cancer. AscoAnnuMeet 2015; 51: 266
    PubMedSuche in Google Scholar
  • 19 Hanf V, Schütz F, Liedtke C. et al. AGO recommendations for the diagnosis and treatment of patients with advanced and metastatic breast cancer: Update. Breast Care (Basel) 2014; 9: 202-209
    CrossrefPubMedSuche in Google Scholar
  • 20 Paoletti C. Abstract OT1-3-01: Characterization of circulating tumor cells from subjects with metastatic breast cancer using the CTC-endocrine therapy index: the COMETI-P2-2012.0 trial. Cancer Res 2013; 73 (24 Suppl.): OT1-3-01
    CrossrefPubMedSuche in Google Scholar
  • 21 Online: http://www.clinicaltrials.gov/ct2/show/NCT01349842 last access: 09/2017
    PubMed
  • 22 Smerage JB, Barlow WE, Hortobagyi GN. et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014; 32: 3483-3489
    CrossrefPubMedSuche in Google Scholar
  • 23 Online: http://www.clinicaltrials.gov/ct2/show/NCT01710605 last access: 09/2017
    PubMed
  • 24 Kataoka Y, Mukohara T, Shimada H. et al. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2010; 21: 255-262
    CrossrefPubMedSuche in Google Scholar
  • 25 Eichhorn PJA, Gili M, Scaltriti M. et al. Phosphatidyinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68: 9221-9230
    CrossrefPubMedSuche in Google Scholar
  • 26 Dupont Jensen J, Laenkholm AV, Knoop A. et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 2011; 17: 667-677
    CrossrefPubMedSuche in Google Scholar
  • 27 Mandel PM. Les acides nucleiques du plasma sanguin chez lʼhomme. CR Acad Sci Paris 1940; 142: 241-253
    PubMedSuche in Google Scholar
  • 28 Casciano I, Vinci AD, Banelli B. et al. Circulating tumor nucleic acids: perspective in breast cancer. Breast Care (Basel) 2010; 5: 75-80
    CrossrefPubMedSuche in Google Scholar
  • 29 Lo YM, Rainer TH, Chan LY. et al. Plasma DNA as a prognostic marker in trauma patients. Clin Chem 2000; 46: 319-323
    PubMedSuche in Google Scholar
  • 30 Sozzi G, Conte D, Leon M. et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003; 21: 3902-3908
    CrossrefPubMedSuche in Google Scholar
  • 31 Leon SA, Shapiro B, Sklaroff DM. et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977; 37: 646-650
    PubMedSuche in Google Scholar
  • 32 Bettegowda C, Sausen M, Leary RJ. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6: 22ra224
    CrossrefPubMedSuche in Google Scholar
  • 33 Dawson SJ, Rosenfeld N, Caldas C. Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 369: 93-94
    CrossrefPubMedSuche in Google Scholar
  • 34 Heidary M, Auer M, Ulz P. et al. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res 2014; 16: 421
    CrossrefPubMedSuche in Google Scholar
  • 35 Madic J, Kiialainen A, Bidard FC. et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer 2015; 136: 2158-2165
    CrossrefPubMedSuche in Google Scholar
  • 36 Board RE, Wardley AM, Dixon JM. et al. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat 2010; 120: 461-467
    CrossrefPubMedSuche in Google Scholar
  • 37 Baselga J, Im SA, Iwata H. et al. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): first results from the randomized, phase III BELLE-2 trial. San Antonio Breast Cancer Symposium 2015; San Antonio, TX, USA; Abstract S6-01.
    PubMed
  • 38 Di Leo A, Ciruelos E, Janni W. et al. BELLE-3: A phase III study of the pan-phosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based treatment. ASCO Annual Meeting 2015; Chicago, Il; Abstract TPS626.
    PubMed
  • 39 Di Leo A, Seok Lee K, Ciruelos E. BELLE-3: a phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment. San Antonio Breast Cancer Symposium 2016; San Antonio, TX, USA; Abstract S4-07.
    PubMed
  • 40 Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-282
    CrossrefPubMedSuche in Google Scholar
  • 41 Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A. et al. D538 G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res 2013; 73: 6856-6864
    CrossrefPubMedSuche in Google Scholar
  • 42 Toy W, Shen Y, Won H. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013; 45: 1439-1445
    CrossrefPubMedSuche in Google Scholar
  • 43 Wang P, Bahreini A, Gyanchandani R. et al. Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions and cell free DNA of breast cancer patients. Clin Cancer Res 2016; 22: 1130-1137
    CrossrefPubMedSuche in Google Scholar
  • 44 Chandarlapaty S, Chen D, He W. et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol 2016; 2: 1310-1315
    CrossrefPubMedSuche in Google Scholar
  • 45 Ma F, Zhu W, Guan Y. et al. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Oncotarget 2016; 7: 66020-66031
    PubMedSuche in Google Scholar
  • 46 Fasching PA, Brucker SY, Fehm TN. et al. Biomarkers in patients with metastatic breast cancer and the PRAEGNANT study network. Geburtsh Frauenheilk 2015; 75: 41-50
    Thieme ConnectPubMedSuche in Google Scholar
  • 47 Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854
    CrossrefPubMedSuche in Google Scholar
  • 48 Roth C, Rack B, Muller V. et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010; 12: R90
    CrossrefPubMedSuche in Google Scholar
  • 49 Madhavan D, Peng C, Wallwiener M. et al. Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. Carcinogenesis 2016; 37: 461-470
    CrossrefPubMedSuche in Google Scholar